Article info

Original research
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

Authors

  • Vania Lo Presti Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Angelo Meringa Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Ester Dunnebach Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Alice van Velzen Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Aida Valera Moreira Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Ronald W Stam Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Rishi S Kotecha Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children’s Hospital, Perth, Western Australia, AustraliaUniversity of Western Australia, Perth, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Anja Krippner-Heidenreich Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Olaf T Heidenreich Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Maud Plantinga Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Annelisa Cornel Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Zsolt Sebestyen Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Jurgen Kuball Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Niek P van Til Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children’s Hospital, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam and Amsterdam Neuroscience, Cellular & Molecular Mechanisms, Amsterdam, The NetherlandsDepartment of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • S Nierkens Princess Máxima Center for Pediatric Oncology, Utrecht, The NetherlandsCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr S Nierkens; S.Nierkens-2{at}prinsesmaximacentrum.nl
View Full Text

Citation

Lo Presti V, Meringa A, Dunnebach E, et al
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

Publication history

  • Accepted March 18, 2024
  • First published April 5, 2024.
Online issue publication 
April 05, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.